About this keynote
Siemens Healthineers Shape Keynote is our annual signature event. It offers a unique blend of market expertise and Siemens Healthineers innovations. The keynote provides access to the knowledge of some of the world’s most respected healthcare thought leaders and unveils exclusive Siemens Healthineers breakthroughs for the first time.
We are sharing inspiring ideas and innovative solutions for three of the biggest challenges faced by healthcare providers:
A world without fear of cancer
To create a world without fear of cancer, we explore how to make oncology care more predictive and more precise
Speakers: Serena Wee, Dr. Arun J. Sanyal, Dr. Amanda Cassie, Dr. Bernhard Meyer
Meet patients where they are
To meet patients where they are, we discuss how to reconfigure care delivery in both low and high acuity settings
Speakers: Dr. Jerome Adams, Dr. Pál Maurovich-Horvat, Dr. Maxime Guye, Dr. Matilde Inglese
Care for those who care for others
To care for those who care for others, we discover how technology can be a key part of the solution to the global healthcare workforce crisis
Speakers: Dr. Reena Nakra, Dr. Rahel Kubik
Highlight Product and Topics
NAEOTOM Alpha with Quantum technology is nothing less than the total reinvention of CT.
Atellica® POC Cardiac Solution
How would a hs-cTnI testing at the POC impact operational workflow?
Smart imaging value chain
Experience outcomes that matter along the smart imaging value chain.
*The products are still under development and not commercially available yet. Its future availability cannot be ensured. Siemens Healthineers neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S. the ELF Test is not for use in the diagnosis of NASH or for the staging of fibrosis. The ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.